Our CEO, Immanuel Lerner will be visiting Singapore, and attending the J-Labs Singapore Family Office Investor Event.
In addition to attending the J-Labs Singapore Family Office Investor Event, he will be in Singapore from September 14-17 for additional meetings with collaborators in the peptide therapeutics space.
Pepticom joins Johnson & Johnson’s global incubator network JLABS EMEA & Singapore, as a virtual member company
Pepticom Ltd. is proud to be a virtual member company of Johnson & Johnson‘s global incubator network, JLABS, in EMEA and Singapore. JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology […]
Our CEO Immanuel Lerner will be attending & presenting at the NextGen Biomed 2025 in London, March 12-13
Join our CEO, Immanuel Lerner for insights on AI-driven peptide drug discovery:📅 March 12:🗝 Keynote – Orally Available Peptides | 9:55 AM💡 Panel – Novel Peptide Therapeutics | 12:30 PM 📅 March 13:🎙 Moderator – Optimizing Drug Candidates | 2:15 PM
Our CEO Immanuel Lerner will be presenting at the DDIF 15th Annual Drug Discovery Innovation Forum in Berlin on September 5th
Our CEO Immanuel Lerner has been selected to speak at the #DDIF 15th Annual Drug Discovery Innovation Forum in Berlin, on September 4-5, 2024!
Our COO Maayan Elias Robicsek will attend Biomed Israel 2025, May 21-23/2024
Our COO Maayan Elias Robicsek is attending Biomed Israel 2025! Come and say hello to learn about our AI drug discovery platform